Who
Ian F. Smith
Director
Company insider
Files Form 4 as: Director, Solid Biosciences; Director, Foghorn Therapeutics; Director, Odyssey Therapeutics; Chief Executive Officer, Stoke Therapeutics; EVP, COO, Vertex Pharmaceuticals; Director, Acorda Therapeutics; Director, Infinity Pharmaceuticals; Director, Ophthotech.
In numbers
- Trades disclosed
- 489
- Buys
- 0
- Sells
- 68
- Bought
- $0
- Sold
- $166.2M
- Companies
- 9
- Companies where not an officer
- 7
- First trade
- 23 Jan 2006
- Last trade
- 2 Oct 2026
- Last filed
- 6 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Oct 2026filed 6 Oct 2026 | SLDB Solid BiosciencesBiotechnology | SEC FORM 4 Code M | —3,440 | filing |
| 2 Oct 2026filed 6 Oct 2026 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,440 at $0.00 | filing |
| 2 Jul 2026filed 7 Jul 2026 | SLDB Solid BiosciencesBiotechnology | SEC FORM 4 Code M | —3,440 | filing |
| 2 Jul 2026filed 7 Jul 2026 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,440 at $0.00 | filing |
| 2 Jul 2026filed 7 Jul 2026 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,440 at $0.00 | filing |
| 2 Jul 2026filed 7 Jul 2026 | SLDB Solid BiosciencesBiotechnology | SEC FORM 4 Code M | —3,440 | filing |
| 24 Jun 2026filed 25 Jun 2026 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $114K28,000 at $4.08 | filing |
| 24 Jun 2026filed 25 Jun 2026 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $114K28,000 at $4.08 | filing |
| 10 Jun 2026filed 11 Jun 2026 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —77,500 at $0.00 | filing |
| 10 Jun 2026filed 11 Jun 2026 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —77,500 at $0.00 | filing |
| 7 May 2026filed 11 May 2026 | ODTX Odyssey Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,393 at $0.00 | filing |
| 7 May 2026filed 11 May 2026 | ODTX Odyssey Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,393 at $0.00 | filing |
| 2 Apr 2026filed 2 Apr 2026 | SLDB Solid BiosciencesBiotechnology | SEC FORM 4 Code M | —3,441 | filing |
| 2 Apr 2026filed 2 Apr 2026 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,441 at $0.00 | filing |
| 2 Apr 2026filed 2 Apr 2026 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,441 at $0.00 | filing |
| 2 Apr 2026filed 2 Apr 2026 | SLDB Solid BiosciencesBiotechnology | SEC FORM 4 Code M | —3,441 | filing |
| 17 Feb 2026filed 19 Feb 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —193,000 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —129,000 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —193,000 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —129,000 at $0.00 | filing |
News
Head to Head Analysis: Caribou Biosciences (NASDAQ:CRBU) & Vertex Pharmaceuticals (NASDAQ:VRTX)VRTX · tickerreport.com · 14 Oct 2026Vertex Pharmaceuticals Incorporated: Vertex to Present New Data on ALYFTREK at the North American Cystic Fibrosis ConferenceVRTX · finanznachrichten.de · 9 Oct 2026
0 headlines in the last 90 days name Ian F. Smith; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.